Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510374 · ClinicalTrials.gov registry record · Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
A Phase 3 study of Intermediate Risk Non-Muscle Invasive Bladder Cancer, sponsored by Ferring Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 454
- Enrollment target
- 20
- Study locations
NCT06510374: Recruiting Phase 3 study of Intermediate Risk Non-Muscle Invasive Bladder Cancer, sponsored by Ferring Pharmaceuticals.
NCT06510374 is a Phase 3 study of Intermediate Risk Non-Muscle Invasive Bladder Cancer that is actively recruiting participants, run by Ferring Pharmaceuticals. The registered enrollment target is 454 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06510374, a Phase 3 study of Intermediate Risk Non-Muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by Ferring Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 454 participants
- Enrollment target
- 20
- Study locations
Study Summary
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Primary Outcome
Recurrence-free survival, defined as the time from the date of randomization to the date of first documented recurrence, progression or death (due to any cause), whichever occurs first during the treatment period.
Conditions Studied
Interventions
- DRUG Nadofaragene Firadenovec
Study Locations (20)
California
- Urology Associates of Central California - Fresno
- American Institute of Research - Los Angeles
- Urology Center of Southern California - Murrieta
- University of California, Irvine - Orange
- Providence Saint John's Cancer Institute - Santa Monica
Florida
- Mayo Clinic - Jacksonville
- Advanced Urology institute - Pinellas - Largo
- Sarasota Memorial Healthcare System - Sarasota
Alabama
- University of South Alabama (USA) Health System - USACM - Mobile
- Urology Associates of Mobile - Mobile
Illinois
- NextStage Clinical Research - Lisle
- Blessing Health System - Quincy
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- Advent Health - Denver
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 3 |
What NCT06510374 shows while recruiting
NCT06510374 is an interventional study that assigns participants to a tested intervention. The registered 454 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Intermediate Risk Non-Muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nadofaragene Firadenovec is the first listed.
NCT06510374 names 20 study sites across 12 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06510374 about?
NCT06510374 is a clinical study titled "Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer". A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
What is the current status of trial NCT06510374?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 454 participants. The study started on 2024-10-01. Estimated completion is 2031-06-30.
What conditions does trial NCT06510374 study?
This clinical trial studies the following conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer.
What interventions are being tested in trial NCT06510374?
The interventions under investigation include: Nadofaragene Firadenovec (DRUG).
Who is sponsoring clinical trial NCT06510374?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510374 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06510374's enrollment target sits among peer trials
454 832nd of 2000 higher than 1,167 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05489211 · 454 participants · Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- NCT05655936 · 454 participants · NA
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
- NCT06935357 · 454 participants · Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI